PARIS, 23 February 2021 – Bryan, Garnier & Co, a leading pan-European investment bank focusing on growth companies, is delighted to announce that it has appointed Christophe Alleman as Co-head of Equity Capital Markets.

Based in Paris, Christophe will take up his role to help further expand Bryan, Garnier & Co’s Equity Capital Markets business.

Christophe has a distinguished career in the investment banking industry with a 25-year career at Société Générale. After 10 years in tech M&A, he developed the bank’s franchises in both SME ECM and DCM, helping the businesses to reach market leadership positions.  Before leaving Société Générale, Christophe headed the Small and Mid-Cap Equity and Debt Capital Markets and led more than 100 public offerings in Europe across multiple industry verticals.  In tech, healthcare and business services, Christophe advised clients such as Altran, Axway, Criteo, DBV Technologies, Illiad, Ingenico, Korian, Orpea Soitec and SopraSteria.

Greg Revenu, Co-founder & Managing Partner states: “Serving our clients throughout their lifecycle and across their capital structure with sector focused M&A and capital markets capabilities allow us to establish long-term partnerships with the most promising European companies. As public capital markets are becoming increasingly attractive for growth companies and their shareholders, the arrival of Christophe is another demonstration of the firm commitment to the success of its clients.  We are thrilled to have Christophe, a longstanding friend of the firm, joining us in this exciting moment.”

Pierre Kiecolt-Wahl, Partner, ECM, adds: “I am very pleased to welcome Christophe to Bryan, Garnier& Co and to join me in co-heading our Equity Capital Markets franchise. Christophe brings a long and established track-record of ECM success in the French Small and Mid-Cap market, which represents the largest pool of publicly listed small and mid-cap companies in Continental Europe. We believe the outlook is bright for this segment and with Christophe on board, we add further capability and means to deliver leading capital markets outcomes for our clients.”

Christophe Alleman comments: “I am very glad to join Bryan, Garnier & Co at a time when the firm is fully benefiting from positive markets dynamics and its unique positioning towards growth companies. I admire what Bryan, Garnier & Co has achieved and with its sector and product expertise, I am very confident we can drive the ECM business to new heights.”

In his role, Christophe will contribute to strengthening the group’s existing ECM activities with a primary focus on the French-speaking European markets, where he will leverage his long-standing experience in the small- and mid-cap segment alongside Bryan, Garnier & Co’s track record of bringing some of the leading innovative and growth companies to the capital markets.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from its longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for BioNTech (NASDAQ), Mcphy Energy (Euronext Paris), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm),  Materialise (NASDAQ), GenSight (Euronext Paris), and  Zealand Pharma (Copenhagen), and Medincell (Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).